Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer

Her2-Receptor Negative Breast Cancer

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

186 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Palbociclib Helwan University	Phase 2	BBB
Exemestane National Cancer Institute (NCI)	Phase 4	BBB
Pembrolizumab UNC Lineberger Comprehensive Cancer Center	Phase 2	BBB
Atezolizumab TransThera Sciences (Nanjing), Inc.	Phase 2	BB
Palazestrant Olema Pharmaceuticals, Inc.	Phase 3	BB

View all 50 →

Same molecule, other indications

Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer is also rated in:

malignant pancreatic neoplasmActive

Indicative · Phase 2

68 / 100

View asset →

biliary tract neoplasmDormant

Indicative · Phase 2

66 / 100

View asset →

pancreatic ductal adenocarcinomaActive

Indicative · Phase 2

66 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →